Glucagon-like peptide-1 (7-36) amide response to low versus high glycaemic index preloads in overweight subjects with and without type II diabetes mellitus

European Journal of Clinical Nutrition

Volumn 61, Issue 12, 2007, Pages 1364-1372

  Milton, J E ^a   Sananthanan, C S ^a   Patterson, M ^a   Ghatei, M A ^a   Bloom, S R ^a   Frost, G S ^a  

^a HAMMERSMITH HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCAGON LIKE PEPTIDE 1 [7-36] AMIDE; GLUCOSE; INSULIN; ORAL ANTIDIABETIC AGENT; PARACETAMOL;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; FLUID INTAKE; FOOD INTAKE; GLUCOSE BLOOD LEVEL; GLYCEMIC INDEX; HORMONE RELEASE; HORMONE RESPONSE; HUMAN; INSULIN BLOOD LEVEL; MALE; MILK; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; STOMACH EMPTYING;

ANIMALS; AREA UNDER CURVE; BLOOD CHEMICAL ANALYSIS; BLOOD GLUCOSE; CROSS-OVER STUDIES; DIABETES MELLITUS, TYPE 2; DIETARY CARBOHYDRATES; FEMALE; GASTRIC EMPTYING; GLUCAGON-LIKE PEPTIDE 1; GLYCEMIC INDEX; HUMANS; INSULIN; MALE; MIDDLE AGED; MILK; OVERWEIGHT; POSTPRANDIAL PERIOD; WATER;

EID: 37049031477     PISSN: 09543007     EISSN: 14765640     Source Type: Journal    
DOI: 10.1038/sj.ejcn.1602654     Document Type: Article

References (33)

1. Adam TC, Westerterp-Plantenga MS (2005). Nutrient-stimulated GLP-1 release in normal-weight men and women. Horm Metab Res 37, 111-117.
2. Adam TC, Westerterp-Plantenga MS (2005). Glucagon-like peptide-1 release and satiety after a nutrient challenge in normal-weight and obese subjects. Br J Nutr 93, 845-851.
3. Brand-Miller J, Holt SH, de Jong V, Petocz P (2003). Cocoa powder increases postprandial insulinemia in lean young adults. J Nutr 133, 3149-3152.
4. Brynes AE, Frost GS, Edwards CM, Ghatei MA, Bloom SR (1998). Plasma glucagon-like peptide-1 (7-36) amide (GLP-1) response to liquid phase, solid phase, and meals of differing lipid composition. Nutrition 14, 433-466.
5. Brynes AE, Lee JL, Brighton RE, Leeds AR, Dornhorst A, Frost GS (2003). A low glycemic diet significantly improves the 24-h blood glucose profile in people with type 2 diabetes, as assessed using the continuous glucose minimed monitor. Diabetes Care 26, 548-549.
6. Flint A, Raben A, Astrup, A, Hoist JJ (1998). Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans. J Clin Invest 101, 515-520.
7. Frost G, Keogh B, Smith D, Akinsanya K, Leeds A (1996). The effect of low-glycemic carbohydrate on insulin and glucose response in vivo and in vitro in patients with coronary heart disease. Metabolism 45, 669-672.
8. Gutniak MK, Linde B, Holst JJ, Efendic S (1994). Subcutaneous injection of the incretin hormone glucagon-like peptide 1 abolishes postprandial glycemia in NIDDM. Diabetes Care 17, 1039-1044.
9. Holt SH, Miller JC, Petocz P (1997). An insulin index of foods: The insulin demand generated by 1000-KJ portions of common foods. Am J Clin Nutr 66, 1264-1276.
10. Hoyt G, Hickey MS, Cordain L (2005). Dissociation of the glycaemic and insulinaemic responses to whole and skimmed milk. Br J Nutr 93 175-177.
11. Hui H, Wright C, Perfetti R (2001). Glucagon-like peptide 1 induces differentiation of islet duodenal homeobox-1-positive pancreatic ductal cells into insulin-secreting cells. Diabetes 50, 785-796.
12. Jarvi AE, Karlstrom. BE, Granfeldt YE, Bjorck IE, Asp NG, Vessby BO (1999). Improved glycemic control and lipid profile and normalized fibrinolytic activity on a low-glycemic index diet in type 2 diabetic patients. Diabetes Care 22, 10-18.
13. Jenkins DJ, Wolever TM, Taylor RH, Barker H, Fielden H, Baldwin JM et al. (1981). Glycemic index of foods: A physiological basis for carbohydrate exchange. Am J Clin Nutr 34, 362-366.
14. Kjems LL, Holst JJ, Volund A, Madsbad S (2003). The influence of GLP-1 on glucose-stimulated insulin secretion: Effects on beta-cell sensitivity in type 2 and nondiabetic subjects. Diabetes 52, 380-386.
15. Kreymann B, Williams G, Ghatei MA, Bloom SR (1987). Glucagon-like peptide-1 7-36: A physiological incretin in man. Lancet 2, 1300-1344.
16. Layer P, Hoist JJ, Grandt D, Goebell H (1995). Real release of glucagon-like peptide-1 (GLP-1). Association with inhibition of gastric acid secretion in humans. Dig Dis Sci 40, 1074-1082.
17. Lugari R, Dei Cas A, Ugolotti D, Finardi L, Barilli AL, Ognibene C et al. (2002). Evidence for early impairment of glucagon-like peptide 1-induced insulin secretion in human type 2 (non insulin-dependent) diabetes. Horm Metab Res 34, 150-154.
18. Nauck MA, Heimesaat MM, Orskov C, Holst JJ, Ebert R, Creutzfeldt W (1993). Preserved incretin activity of glucagon-like peptide 1 [7-36 amidel] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus. J Clin Invest 91, 301-307.
19. Nilsson M, Stenberg M, Frid AH, Hoist JJ, Bjorck IM (2004). Glycemia and insulinemia in healthy subjects after lactose-equivalent meals of milk and other food proteins: The role of plasma amino acids and incretins. Am J Clin Nutr 80, 1246-1153.
20. Ostman EM, Liljeberg Elmstahl HG, Bjorck IM (2001). Inconsistency between glycemic and insulinemic responses to regular and fermented milk products. Am J Clin Nutr 74, 96-100.
21. O'Donovan DG, Doran S, Feinle-Bisset C, Jones KL, Meyer JH, Wishart JM et al. (2004). Effect of variations in small intestinal glucose delivery on plasma glucose, insulin, and incretin hormones in healthy subjects and type 2 diabetes. J Clin Endocrinol Metab 89, 3431-3435.
22. Ranganath LR, Beety JM, Morgan LM, Wright JW, Howland R, Marks V (1996). Attenuated GLP-1 secretion in obesity: Cause or-consequence? Gut 38, 916-919.
23. Rawlins MD, Henderson DB, Hijab AR (1997). Pharmacokinetics of paracetamol (acetaminophen) after intravenous and oral administration. Eur J Clin Pharmacol 11, 283-286.
24. Shively CA, Apgar JL, Tarka Jr SM (1986). Postprandial glucose and insulin responses to various snacks of equivalent carbohydrate content in normal subjects. Am J Clin Nutr 43, 335-342.
25. Tarling MM, Toner CC, Withington. PS, Baxter MK, Whelpton R, Goldhill DR (1997). A model of gastric emptying using paracetamol absorption in intensive care patients. Intensive Care Med 23, 256-260.
26. Teff KL, Engelman K (1996). Palatability and dietary restraint: Effect on cephalic phase insulin release in women. Physiol Behav 60 567-573.
27. Todd JF, Wilding JP, Edwards CM, Khan FA, Ghatei MA, Bloom SR (1999). Glucagon-like peptide-1 (GLP-1): A trial of treatment in non-insulin-dependent diabetes mellitus. Eur J Clin Invest 27 533-536.
28. Toft-Nielsen MB, Damholt MB, Madsbad S, Hilsted LM, Hughes TE, Michelsen BK et al. (2001). Determinants of the impaired secretion of glucagon-like peptide-1 in type 2 diabetic patients. J Clin Endocrinol Metab 86, 3717-3723.
29. Truswell AS (1992). Glycaemic index of foods, Eur J Clin Nutr, 46 (Supp 2), S91-S101.
30. Verdich C, Toubro S, Buemann B, Lysgard Madsen J, Juul Holst J, Astrup A (2001). The role of postprandial releases of insulin and incretin hormones in meal-induced satiety - effect of obesity and weight reduction. Int J Obes Relat Metab Disord 25, 1206-1214.
31. Vilsboll T, Krarup T, Deacon CF, Madsbad S, Holst JJ (2001). Reduced postprandial concentrations of intact biologically active glucagon-like peptide 1 in type 2 diabetic patients. Diabetes 50, 609-613.
32. Vilsboll T, Krarup T, Sonne J, Madsbad S, Volund A, Juul AG et al. (2003). Incretin secretion in relation to meal size and body weight in healthy subjects and people with type 1 and type 2 diabetes mellitus. J Clin Endocrinol Metab 88, 2706-2713.
33. Zander M, Madsbad S, Madsen JL, Holst JJ (2002). Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: A parallel-group study. Lancet 359, 824-830.